AbbVie’s Japan Sales Sag 13% in 2021 as Off-Year Price Cuts, Synagis Return Weigh

AbbVie Japan President James Feliciano AbbVie saw its Japan revenue dwindle 13% over the prior year to 99 billion yen in 2021, dented by “off-year” price reductions and the return of its rights for the RSV antibody Synagis (palivizumab) to...read more